Results 211 to 220 of about 41,938 (307)

EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy. [PDF]

Cancer Sci
Gao J, Jiao X, Ren F, Wu X, Tan J, Bai Y, Dai Y, Shen L, Wu C, Shen L.   +9 more
europepmc   +1 more source

Sensing and Reprogramming Surface Receptor Activation With Synthetic Transcriptional Circuits

Advanced Science, Volume 13, Issue 25, 4 May 2026.
A synthetic receptor‐signalling induced transcription (RESIT) circuit is designed based on receptor activation mediated split protease complementation and release of membrane‐tethered synthetic transcriptional modules. The RESIT system enables probing Ca2+ entry, receptor tyrosine kinase (RTK) activities and Ras activation, and reprogramming RTK ...
Fei Liu, Mei Yuan, Li‐Juan Tang, Fenglin Wang, Xia Chu, Jian‐Hui Jiang   +5 more
wiley   +1 more source

Cytomegalovirus Infection After Chimeric Antigen Receptor T-Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. [PDF]

Transpl Infect Dis
Han J, Lim SY, Hyung J, Cho H, Yoon DH, Kim SH.   +5 more
europepmc   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, Volume 101, Issue 5, Page 986-997, May 2026.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

Parallel Sequencing of the Two Arms on a Bispecific Antibody by Electron Capture Dissociation on a timsOmni Platform Reveals Several By-products in the Controlled Fab-arm Exchange Process. [PDF]

Anal Chem
Stroganova I, Ollivier S, Radić L, Smyrnakis A, Kosmopoulou M, Schinkel J, Sliepen K, Greisch JF, Heck AJR.   +8 more
europepmc   +1 more source

Tumor Anti‐Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Vascular normalization, one promising anti‐angiogenic strategy, has the potential to enhance vascular perfusion and elevate the infiltration of immune cells into tumors by rectifying aberrant tumor blood vessels. This results in the enhancement of immunotherapy.
Yu Tang, Yuyan Ding, LiPing Wang, Yujiao Yang, Youwei Han, Peng Zhou, Huiheng Qu, Kaiyuan Deng, Jiazeng Xia   +8 more
wiley   +1 more source

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities. [PDF]

Nat Commun
Guan J, Chia T, Li B, Zhu T, Liao Z, Deng J, Fu F, Wu W, Liu C, Liu Y, Li N, Yue L, Cao L, Lu J, Zhu M, Ling X, Zheng H, Lin S, Li L, Zhou S, He K.   +20 more
europepmc   +1 more source

Differences in Perspectives and Policies Regarding End‐of‐Life Care Between Hematologists and Gastroenterologists

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Patients with hematologic malignancies often receive aggressive treatment until the terminal phase and transition to end‐of‐life (EOL) care less frequently than those with solid tumors. A 2015 survey compared hematologists' and solid tumor‐oncologists' attitudes toward EOL care, revealing differences.
Takuya Matsunaga, Kazuyuki Murase, Shiro Hinotsu, Kohichi Takada, Takanori Teshima, Ken Sato, Yasuhiro Nagaoka, Takayuki Machino, Yusuke Sugama, Masayoshi Kobune, Kunihiko Ishitani   +10 more
wiley   +1 more source

Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights. [PDF]

Front Immunol
Chen W, Zhou A, Zhou Y.
europepmc   +1 more source

Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective?

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang, Yisen Cao, Yuan Ren, Yuhang Zhang, Liang Wang   +4 more
wiley   +1 more source